Danthron prevents pulmonary fibrosis through improving mitochondrial function by upregulating carboxylesterase 3 Authors: Boyu Li, Rongman Xu, Hongyan Zheng, Zhen Tian, Shanshan Wang, Sicheng Xu, Danlei Yang, Jianping Zhao, Jungang Xie Published: 2026 ABSTRACT AbstractBackgroundIdiopathic pulmonary fibrosis (IPF) is marked by excessive deposition of extracellular matrix (ECM) and persistent fibroblast activation in the lungs, posing challenges for advancing effective treatment strategies. Danthron, a natural anthraquinone derivative extracted from traditional Chinese medicine rhubarb, exhibits antitumor and antioxidant efficacy.MethodsA bleomycin (BLM)-induced pulmonary fibrosis (PF) mouse model and human precision-cut lung slices (hPCLSs) stimulated with a pro-fibrotic solution were employed. The therapeutic effects of danthron on PF were measured by histological manifestations, immunostaining and expression levels of fibrotic markers. Human fibroblasts (HFs) were utilized to explore the underlying mechanism of danthron on fibroblast function.ResultsOur data showed that danthron significantly mitigated BLM-induced PF by reducing collagen deposition and Ashcroft scores in mice. Danthron also suppressed the abundance of fibrotic markers in mouse lungs and hPCLSs. Additionally, danthron impeded the transition of lung fibroblasts to myofibroblasts while promoting their dedifferentiation. Mechanistically, the anti-fibrotic effect of danthron was associated with the upregulation of carboxylesterase 3 (CES3), which consequently enhanced mitochondrial function and mitophagy in fibroblasts. Pharmacological CES3 inhibition (WWL229) reversed these effects, whereas genetic CES3 overexpression potentiated its mitochondrial benefits. Moreover, WWL229 nullified the beneficial effects of danthron in BLM-induced PF. The downregulation of CES3 was identified in IPF patients, which exhibited a negative correlation with fibrotic genes.ConclusionsThis study demonstrated danthron as a valuable experimental tool for identifying relevant targets in preclinical models while underscoring CES3 as a potential therapeutic target for PF.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12931-026-03753-9.Keywords: Pulmonary fibrosis, Danthron, Fibroblast activation, CES3, Mitochondria Introduction Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic respiratory condition associated with aging that ultimately results in death. It has been demonstrated that there is a consistent pattern of alveolar epithelium injury and the atypical accumulation of myofibroblasts in IPF [1]. With its diverse manifestations, IPF is a prevalent condition among the elderly, characterized by a poor prognosis, with an average survival time of 3–5 years post-diagnosis [2]. Pirfenidone and nintedanib are the sole approved anti-fibrotic treatments; however, they offer only symptomatic relief without halting disease advancement or restoring lung function. Additionally, both medications pose tolerability challenges [3, 4], underscoring the pressing requirement for innovative therapeutic approaches against PF. When lung injury happens, fibroblasts encounter pro-fibrotic cytokines, including transforming growth factor-β1 (TGF-β1) and connective tissue growth factor (CTGF) [5, 6]. This exposure results in fibroblast proliferation and their transformation into myofibroblasts through fibroblast-to-myofibroblast transition (FMT). Myofibroblasts are key effectors with high expression of α-SMA, accumulating in the pulmonary mesenchyme and secreting excessive extracellular matrix (ECM), ultimately resulting in alveolar structural damage and scarring formation [7]. TGF-β1 is the key pro-fibrotic cytokine that maintains ongoing fibroblast activation and myofibroblast differentiation during the development of IPF [8]. Consequently, given the influence of TGF-β1 on ECM accumulation and FMT, therapeutic approaches aimed at inhibiting TGF-β1 production or blocking its signaling pathways represent valuable strategies for managing IPF. Danthron, or 1,8-Dihydroxyanthraquinone, is a natural anthraquinone derivative extracted from traditional Chinese medicine rhubarb. Previous studies have indicated that danthron suppresses the proliferation and invasion of activated endothelial cells [9], exerts antiangiogenic and antioxidant effects in cancer cells [9], and alleviates metabolic dysfunction-associated steatotic liver disease (MASLD) in obese mice by regulating mitochondrial biogenesis, fatty acid oxidation (FAO) and lipid synthesis [10]. Considering the decreased FAO and dysregulated mitochondrial function in IPF fibroblasts [11] and similar pathogenesis between fibrosis and cancer [12], we hypothesized that danthron could potentially demonstrate anti-fibrotic properties in IPF by targeting mitochondrial metabolism and fibroblast activation. Given its potential health risks, danthron was subject to rigorous safety measures during both in vivo and in vitro experiments to minimize the risk of exposure. In this study, our findings demonstrated the efficacy of danthron in ameliorating bleomycin (BLM)-induced PF in mice and pro-fibrotic solution-induced human precision-cut lung slices (hPCLSs). Mechanistically, danthron suppressed fibroblast activation induced by TGF-β1, improved mitochondrial function, and promoted mitophagy by upregulating CES3 expression. Furthermore, as a CES3 inhibitor, WWL229 reversed the protective effects of danthron both in vivo and in vitro. While genetic overexpression of CES3 synergistically amplified the danthron-mediated mitochondrial improvements. These findings indicated that danthron showed potential as an effective experimental tool for identifying relevant targets in PF, and demonstrated CES3 as a therapeutic target for IPF. Materials and methods Reagents and antibodies Danthron (99.41% purity) and WWL229 (99.49% purity) were purchased from MedChemExpress and dissolved in DMSO for in vitro and in vivo experiments following the supplier's instructions. Details for other reagents and antibodies were provided in Table S1 and S2. Patient specimens The Human Assurance Committee of Tongji Hospital approved the ethical aspects of these studies (Reference No. TJ-IRB202408057). Lung tissue samples were obtained from 3 IPF patients and 3 control subjects, who underwent lung transplantation or surgical resection of lung masses in thoracic surgery. IPF lung specimens were collected from individuals who fulfilled the diagnostic criteria for IPF as outlined in the joint consensus guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS) [13]. Control samples were macroscopically normal tissue taken ≥ 5 cm from tumour margins of lung-cancer resections. The samples were collected at Tongji Hospital with the consent of all participants. The clinical characteristics of patients in immunostaining analysis were summarized in Table S3. Animal experiments The Animal Care and Use Committee of Tongji Hospital (TJH-202307031) granted approval for all experimental protocols. Animal care and experimental procedures were performed following the Guidelines for Ethical Review of Laboratory Animal Welfare (GB/T 35892–2018). The male C57BL/6 mice (6–8 weeks old) were obtained from Vital River (Beijing, China) and kept in a pathogen-free animal facility with a 12:12-h light/dark cycle. The sample size of each group is 5. Mice were randomly assigned to different groups. The chemical structure of danthron was shown in Fig. S1A, and the chemical structure of WWL229 was shown in Fig. S7A. With ether inhalation of anesthesia, the mice were intratracheally administered 1.7 mg/kg of BLM in 50 μL of PBS. An equal amount of PBS was administered to the control group. After the BLM administration, mice received a 7-day oral administration of danthron at 60 mg/kg from d 14 to d 21. Simultaneously, a 7-day intraperitoneal injection of WWL229 at 30 mg/kg was administrated from d 14 to d 21. All mice were humanely euthanized at d 21 to analyze PF. Generation and culture of hPCLSs Lung tissues from 4 control subjects were collected for the hPCLSs experiment. The tissues were thoroughly washed with PBS to remove blood cells. Then we gently filled them with an appropriate volume of 2% low-melting agarose (Sigma, MO, USA) at 37 °C, depending on the size of the lungs, to allow them to expand fully. Subsequently, the tissues were immediately immersed in pre-chilled PBS to allow the agarose to solidify and stabilize the lung structure. The tissues were cut into 400 μm thick slices following solidification using a Compressor (VF-300-0Z, Precisionary, CA, USA). The hPCLSs were cultured at 37 °C in 1 mL of DMEM phenol red-free medium supplemented with 1% penicillin/streptomycin and 0.5% FBS. Following a 1-h pretreatment with 20 μM danthron, hPCLSs were subjected to a pro-fibrotic solution comprising 20 ng/mL TGF-β1, 10 ng/mL TNF-α, 20 ng/mL PDGF-AB, and 5 μM LPA for 24 h. The clinical characteristics of the subjects were summarized in Table S4. Histological analysis Human lung and mice left lung tissues were collected and immersed in 4% paraformaldehyde and fixed for 24 h at room temperature. For mice lung tissues, sectioning at the hilum into two equal parts was performed during embedding, ensuring that both cross-sectional surfaces were fully exposed while the lung tissue was evenly impregnated with paraffin in an expanded form. The sections were cut into 5 μm thick slices to obtain two large, non-consecutive cross-sections, which were subsequently stained with Sirius red, Masson's trichrome, and hematoxylin and eosin (H&E) following standard protocols. Fibrosis severity was evaluated by the Ashcroft scoring method, which utilizes a scale ranging from 0 to 8. Eight different fields per section from each mouse were randomly selected to assess the fibrotic severity. The Ashcroft scoring was independently conducted by two researchers with lung histopathology experience in a blinded manner. Immunostaining analysis Immunostaining was performed on paraffin sections of lung tissues obtained from IPF patients and mice. The primary antibodies used in this experiment included anti-Fibronectin, anti-CollagenⅠ, anti-CES3, anti-α-SMA, anti-LC3B, anti-PINK1, anti-CD68, and anti-pro-SPC. To visualize the labeled proteins, fluorescent secondary antibodies specific to the respective species were utilized for staining. The nuclei were counterstained using DAPI. Fluorescence images were captured by Olympus (Melville, NY, USA). We adjusted the exposure time according to the fluorescence intensity and fixed the time of each channel. All images were processed with appropriate and fixed parameters using Photoshop, and the quantification of fluorescence intensity was conducted using Image J software. Five to eight different fields per sample were randomly selected for quantification of fluorescence intensity across all markers. Isolation and treatment of human primary fibroblasts Human primary fibroblasts employed in all in vitro experiments were isolated from age- and sex-matched control subjects. Following immediate collection, lung tissues were finely minced and incubated in 2 mL of DMEM with 10% FBS and 1% penicillin/streptomycin. Afterward, the culture medium was changed every 24 h. Experiments were carried out using passage 3–5 cells. Human fibroblasts (HFs) were pretreated with 20 μM danthron for 1 h and then stimulated with 10 ng/mL TGF-β1 for 24 h to evaluate the effect of danthron on fibroblast activation. After stimulating fibroblasts with TGF-β1 for 24 h, danthron was given for another 24 h to investigate the effect of danthron on fibroblast dedifferentiation. Western blot analysis Fibroblasts and lung tissue lysates were prepared with RIPA lysis buffer. Western blot analysis was carried out according to established protocols using primary antibodies. HRP-conjugated mouse IgG and rabbit IgG were utilized as secondary antibodies. The quantification of gray values was conducted using Image J software. RT-PCR analysis Total RNA was extracted from lung tissues and human primary lung fibroblasts using TRlzol reagent according to standard protocols, followed by cDNA synthesis with a reverse transcriptase kit. The RT-PCR assays were performed using SYBR Green mix on a CFX96 Real-Time PCR Detection system (Bio-Rad Laboratories, CA, USA). Gapdh and Actb mRNA levels were utilized as internal controls for normalization. All reagents were purchased from Takara (Tokyo, Japan). The primer pairs used for RT-PCR were summarized in Table S5. Flow cytometry HFs were digested into individual cells using trypsin, followed by staining with α-SMA-FITC as per the manufacturer's instructions. Afterward, the stained cells were analyzed by flow cytometry (Beckman, CA, USA), and data analysis was performed utilizing FlowJo V10 software. JC-1 assay The presence of JC-1 aggregates (red fluorescence) characterizes intact mitochondrial function, in contrast to the monomeric form (green fluorescence) observed with diminished mitochondrial membrane potential (MMP). The treated fibroblasts were harvested and then exposed to JC-1 working buffer (Beyotime, Shanghai, China) under dark conditions for 20 min at 37 °C. Subsequently, the cells underwent two rounds of washing with JC-1 buffer at 600 g for 5 min each. Utilizing the Biotek Synergy2 multifunction measuring instrument (Biotek, Winooski, Vermont, USA), the intensity of red fluorescence (Ex/Em = 530/590 nm) and green fluorescence (Ex/Em = 485/530 nm) was measured. Measurement of intracellular ATP level Cellular ATP levels were detected by the ATP assay kit (Beyotime, Shanghai, China), and then we used protein contents to correct the different samples for comparison. Apoptosis assay Apoptosis was detected by the Annexin V/PI apoptosis detection kit (Beyotime, Shanghai, China). HFs were collected and incubated with Annexin V-FITC and propidium iodide (PI) for 10 min at room temperature in the dark. The apoptosis of cells was analyzed by flow cytometry. Early apoptotic cells only showed FITC fluorescence, and late apoptotic cells showed FITC and PE fluorescence. Intracellular ROS assay The ROS assay kit detected intracellular ROS level (Beyotime, Shanghai, China). HFs were collected and incubated with DCFH-DA for 30 min at 37 °C in the dark and then analyzed by flow cytometry. Plasmid transfection HFs were seeded into 12-well plates. Upon reaching 60% density, cells were transiently transfected with 1 µg/mL CES3-overexpression plasmid using Lipofectamine 3000 according to the manufacturer's protocol. Transmission electron microscopy (TEM) HFs were fixed with glutaraldehyde and osmium tetroxide, stained with uranyl acetate, dehydrated through a graded ethanol series, and embedded for ultrathin sectioning. Images were captured using a TEM (Hitachi, Tokyo, Japan). Autophagic flux monitoring assay Autophagic flux was assessed in HFs using a tandem RFP-GFP-LC3B adenovirus reporter (Genechem, China). HFs were transfected with the virus according to the instructions and then treated as described above. Images were examined by a laser scanning confocal microscope. Mitochondrial network imaging analysis HFs were stained by Mito-Tracker Deep Red FM (Beyotime, China) to visualize mitochondrial networks. The mitochondrial morphology was evaluated by laser scanning confocal microscopy (Olympus, Japan). RNA sequence and data analysis Total RNA was isolated from HFs treated with or without TGF-β1 and danthron. Metware Biotechnology Co., Ltd. (Wuhan, China) conducted sequencing of the cDNA libraries on the Illumina platform. DESeq2 was employed to perform differential expression analysis between groups, and to obtain the set of differentially expressed genes (DEGs) between the two biological conditions. DEGs were identified based on the criteria of |log₂FC|> 1 and p < 0.05. We used volcano plot to visualize the overall distribution of DEGs. Each group included three independent biological replicates. Bioinformatics analysis The gene expression microarray datasets related to IPF (GSE47460, GSE53845, GSE135099) were sourced from the Gene Expression Omnibus dataset (https://www.ncbi.nlm.nih.gov/gds). We included 108 control subjects and 160 IPF patients from GSE47460, 40 IPF patients from GSE53845, and fibroblasts isolated from 15 IPF patients with or without TGF-β1 stimulation from GSE135099. Statistical analysis The mean ± SEM was used to present the data, with a minimum of three independent replicates conducted for each experiment. Statistical analyses were conducted using GraphPad Prism software (San Diego, CA, USA). The Student's t-test with Welch's correction compared two experimental groups with unpaired data. The one-way ANOVA with Bonferroni's correction was employed to compare multiple groups. Pearson's correlation was utilized to conduct correlation analysis. All experiments defined p < 0.05 as statistical significance. *p < 0.05; **p < 0.01; ***p < 0.001, ns = no significance. Results Danthron alleviated BLM-induced PF in mice The therapeutic effects of danthron on BLM-induced PF were investigated through intragastric administration beginning on d 14 following BLM treatment (Fig. 1A). First, we evaluated the safety profile of danthron in vivo. Serum biochemical analyses confirmed no signs of acute danthron-induced toxicity on liver or kidney function in mice, as reflected by the detected values of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CR), and urea (UREA) within the physiological range (Fig. S1B-E). Meanwhile, H&E staining of the heart, liver, spleen, kidney, and intestine revealed no pathological changes (Fig. S1F). Importantly, danthron monotherapy did not alter lung histology and collagen deposition in healthy mice (Fig. S1G, H), excluding non-specific pulmonary effects. The histopathological changes of lung tissues were demonstrated by H&E, Masson and Sirius Red staining (Fig. 1C-F). Our data revealed that BLM led to severe disruption of lung structure and overabundant collagen accumulation, as shown by the blue staining in Masson's trichrome and red staining in Sirius Red. Surprisingly, this deposition was notably diminished upon danthron treatment. Furthermore, danthron inhibited the formation of typeⅠcollagen fibers, which exhibited a distinct strong orange-yellow hue under polarized light and were notably elevated in the bronchial area of BLM-induced lungs. Additionally, BLM-induced lungs showed higher Ashcroft scores, which were significantly reduced with danthron treatment (Fig. 1B). These findings suggested that pulmonary fibrosis was successfully induced in the mouse model and danthron exhibited significant efficacy in alleviating PF. Danthron mitigated lung fibrosis in the BLM-induced model. A Establishment of a BLM-induced model of pulmonary fibrosis and the method of drug delivery utilized for danthron in mice. B Ashcroft score for the severity of fibrosis (n = 5). C-F Representative images of H&E (C), Masson (D), and Sirius Red staining (E, F). Scale bar = 500 μm (the upper of C, D, E), 100 μm (the lower of C, D, E and F). Black boxes were used to magnify the typical pathologic changes. Data were presented as mean ± SEM, ***p < 0.001 Danthron reduced fibrotic markers expression in mice Subsequently, the abundance of fibrotic markers in lung homogenates was measured to evaluate the impact of danthron on PF. In the danthron-treated group, we found lower protein levels of Fibronectin and CollagenⅠcompared to the BLM group (Fig. 2A). Similarly, RT-PCR results demonstrated that danthron reduced the mRNA levels of Fn1 and Col1a1 (Fig. 2B). Additionally, immunostaining showed a notable increase in ECM deposition in the lungs following BLM induction, which was substantially alleviated by danthron (Fig. 2C, D). These data collectively indicated that danthron mitigated PF in mice. Danthron reduced fibrotic markers in mice with BLM-induced fibrosis. A Representative western blot images and quantitative analysis of Fibronectin (FN) and CollagenⅠ(n = 5). B RT-PCR analysis of Fn1 and Col1a1 (n = 5). C, D Representative immunostaining images and relative fluorescence intensity analysis of α-SMA and FN in mouse lungs (n = 5). Scale bar = 50 μm. Data were presented as mean ± SEM, **p < 0.01, ***p < 0.001 Danthron alleviated fibrotic phenotypes in hPCLSs induced by pro-fibrotic solution Further, we explored the effect of danthron on hPCLSs. CCK-8 assay (Fig. S2A) and immunostaining of pro-SPC and Vimentin (Fig. S2B, C) confirmed that hPCLSs retained intact alveolar architecture and maintained high viability throughout the experimental period. Histological evaluation (Fig. 3A, B) revealed that danthron significantly decreased collagen deposition upon a pro-fibrotic solution induction. We evaluated the expression of Fibronectin and α-SMA in hPCLSs. Danthron markedly reduced these fibrotic protein levels, as shown by western blot (Fig. 3C). Similarly, immunostaining of α-SMA and CollagenⅠconfirmed these observations (Fig. 3D, E). In summary, our human ex vivo lung fibrosis model provided compelling evidence that danthron possessed significant anti-fibrotic efficacy in human lung tissue, manifested as restored histological integrity and attenuated expression of fibrosis-related proteins. Danthron attenuated fibrotic effects in hPCLSs exposed to a pro-fibrotic solution. A, B Representative images of Masson and Sirius Red staining. C Representative western blot images and quantitative analysis of FN and α-SMA (n = 4). D, E Representative immunostaining images and relative fluorescence intensity analysis of α-SMA and CollagenⅠin hPCLSs (n = 4). Scale bar = 50 μm. Data were presented as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001 Danthron inhibited TGF-β1-induced activation of lung fibroblasts into myofibroblasts CCK-8 assay, western blot, and RT-PCR results suggested that danthron with a concentration of 20 μM exhibited no cytotoxicity and significantly inhibited Fibronectin expression in vitro (Fig. S3A-C). Thus, the concentration of 20 μM danthron was utilized for the subsequent experiments. To explore the inhibitory impact of danthron on fibroblast activation, human fibroblasts were pretreated with danthron for 1 h and then exposed to 10 ng/mL of TGF-β1 for 24 h. Our results revealed that danthron reduced the expression of fibrosis-related genes (FN1, ACTA2, COL1A1, COL1A2, COL3A1, CTGF, CTHRC1, and MMP2) in TGF-β1-induced HFs (Fig. 4A). The protein levels of Fibronectin and α-SMA were suppressed by danthron (Fig. 4B). Further, flow cytometry analysis indicated an increase in the percentage of α-SMA positive HFs due to TGF-β1 stimulation, which was reduced by danthron (Fig. 4C). Meanwhile, immunostaining of Fibronectin in HFs showed similar results (Fig. 4D). Danthron suppressed TGF-β1-induced fibroblast activation. Following pretreatment with danthron, HFs were stimulated with TGF-β1 for a period of 24 h. A RT-PCR analysis of FN1, ACTA2, COL1A1, COL1A2, COL3A1, CTGF, CTHRC1, and MMP2 in HFs (n = 4). B Representative western blot images and quantitative analysis of FN and α-SMA (n = 3). C Flow cytometry of α- SMA positive HFs (n = 3). D Representative immunostaining images and relative fluorescence intensity analysis of FN in HFs (n = 3). Scale bar = 50 μm. Data were presented as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001 Previous studies suggested that danthron activates PPAR-α signaling to enhance fatty-acid oxidation (FAO) and exerts antioxidant effects by reducing reactive oxygen species (ROS) production. We therefore aimed to investigate whether the protective effects of danthron rely on these pathways. We quantified the mRNA levels of PPARα signaling genes (PPARA, CPT1A, ACOX1, and SIRT1) and antioxidant-related genes, including Nrf2 pathway genes (HMOX1, NFE2L2, and NQO1) and NOX4 (which is involved in ROS production). Contrary to expectations, danthron neither reversed TGF-β1-induced downregulation of FAO-associated genes nor enhanced the expression of antioxidant-related genes (Fig. S4A, C). Consistently, no significant difference in intracellular ROS levels was detected between the TGF-β1 and TGF-β1 + Danthron groups (Fig. S4B). Collectively, these data demonstrated that danthron suppressed fibroblast activation through an alternative regulatory mechanism. In addition, we investigated whether danthron could promote myofibroblast dedifferentiation. Myofibroblasts undergoing dedifferentiation transform into cells characterized by a significant decrease in ECM production and fibrotic protein expression. We stimulated HFs with TGF-β1 for 24 h and then administered danthron for another 24 h. Our results demonstrated that danthron reversed TGF-β1-induced upregulation of fibrotic genes, including FN1, ACTA2, COL1A1, COL1A2, COL3A1, CTGF, CTHRC1, and MMP2 (Fig. S5A). Meanwhile, Fibronectin and α-SMA protein levels exhibited similar results (Fig. S5B). To further investigate whether danthron promoted the lineage transdifferentiation of myofibroblasts into lipofibroblasts, we examined the expression of lipogenic differentiation genes. However, our data showed no significant differences in the expression of PLIN2 and PPARG with danthron treatment (Fig. S5C). Furthermore, we investigated whether danthron-induced myofibroblast dedifferentiation sensitized them to apoptosis. Notably, danthron treatment markedly enhanced apoptosis in HFs compared with TGF-β1 stimulation alone (Fig. S5D). Mechanistically, this restoration of apoptosis sensitivity was associated with the downregulation of the pro-survival genes BIRC5, MYC, and CCND2 and the upregulation of the pro-apoptotic genes APAF1, CASP9, and CDKN1C (Fig. S5E). Taken together, danthron inhibited fibroblast to myofibroblast transition, as well as promoted myofibroblast dedifferentiation by driving cells toward an apoptosis-sensitive phenotype. Upregulation of CES3 mediated the anti-fibrotic effects of danthron To characterize the molecular mechanisms underlying danthron's anti-fibrotic effects, we performed RNA-seq analysis on HFs cultured in vitro and stimulated with TGF-β1 in the presence or absence of danthron. DEGs were filtered using cut-offs of |log₂FC|> 1 and p < 0.05. Compared with the TGF-β1-treated group, the control group exhibited 2393 DEGs, of which 1156 were up-regulated and 1237 were down-regulated. While compared with the TGF-β1-treated group, the TGF-β1 + Danthron group exhibited 419 DEGs, of which 235 were up-regulated and 184 were down-regulated. Among all differential genes, Carboxylesterase 3 (CES3) exhibited significantly elevated expression with danthron treatment (Fig. 5A, B). As enzymes from the endoplasmic reticulum, carboxylesterases were extensively studied in metabolic diseases [14]. Danthron upregulated CES3 to attenuate TGF-β1-induced fibroblast activation and BLM-induced pulmonary fibrosis. A, B Volcano plot labeled for CES3 and pro-fibrotic genes. C Representative western blot images and quantitative analysis of Ces3 in mice (n = 5). D Representative immunostaining of Ces3 expression in the mouse lung fibroblasts. E Representative western blot images and quantitative analysis of CES3 in HFs (n = 3). F RT-PCR analysis of CES3 in HFs (n = 4). Following pretreatment with WWL229, HFs were stimulated with TGF-β1 and danthron for 24 h. G Representative western blot images and quantitative analysis of FN and α-SMA in HFs (n = 4). H Representative images of H&E, Masson, and Sirius Red staining. I Representative immunostaining of α-SMA in mouse lung sections. J RT-PCR analysis of Fn1 and Col1a1 in mice (n = 5). Scale bar = 500 μm (the upper of H), 100 μm (the lower of H), 50 μm (D and H). Black boxes were used to magnify the typical pathologic changes. Data were presented as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001 We explored whether the anti-fibrotic effects of danthron were related to CES3. In the lung tissues of mice induced by BLM, we observed that Ces3 was reduced compared to the control group, and danthron increased Ces3 levels (Fig. 5C). Immunostaining of mouse lung sections showed similar results of Ces3 expression in fibroblasts (Fig. 5D). In vitro, the expression of CES3 was downregulated by TGF-β1 stimulation, which was restored by danthron (Fig. 5E, F). Furthermore, we profiled Ces3 expression in pulmonary macrophages across the Control, BLM and BLM + Danthron groups, immunostaining revealed comparable Ces3 expression in macrophages among these groups (Fig. S6). WWL229, a specific CES3 inhibitor, was utilized to elucidate CES3's role in fibrosis progression. WWL229 has been reported to selectively target and inhibit CES3 activity without altering its abundance [15]. Our results demonstrated that WWL229 upregulated the expression of Fibronectin and α-SMA compared to the TGF-β1 + Danthron group (Fig. 5G). The delivery protocol for danthron and WWL229 in the BLM-induced model was shown in Fig. S7B. Histological and immunostaining analyses revealed that WWL229 co-treatment significantly increased collagen deposition compared with the BLM + Danthron group (Fig. 5H, I). Similarly, RT-PCR results demonstrated that WWL229 elevated the mRNA levels of Fn1 and Col1a1 relative to the BLM + Danthron group (Fig. 5J). Additionally, representative images of lung sections, Ashcroft scores and body weight curves for the Control, BLM, BLM + Danthron, and BLM + Danthron + WWL229 groups were shown in Fig. S7C-F and Fig. S8A-D. Collectively, these findings implied that CES3 upregulation in fibroblasts mediated the anti-fibrotic effects of danthron, which were reversed by WWL229 both in vivo and in vitro. Upregulation of CES3 by danthron enhanced mitochondrial function and mitophagy in fibroblasts Accumulating evidence indicates that mitochondrial dysfunction is critically involved in the development and progression of IPF [16]. The decreased mitochondrial membrane potential (MMP) represents mitochondrial damage. Danthron improved the decreased MMP induced by TGF-β1, which was countered by WWL229 (Fig. 6A). We also detected intracellular ATP production and supernatant lactate levels. The data suggested that danthron increased ATP synthesis and inhibited lactate production in HFs, while WWL229 reversed these effects (Fig. 6B, C). Additionally, exogenous lactate supplementation in HFs abolished the downregulation of Fibronectin and α-SMA in the TGF-β1 + Danthron group, revealing a close association between the anti-fibrotic effects of danthron and suppressed lactate production (Fig. 6D). Mitophagy regulates mitochondrial quality, and its downregulation contributes to fibroblast activation. We thus examined the effect of danthron on mitophagy. Analysis of the GSE135099 dataset revealed a positive correlation between CES3 and the key mitophagy gene PINK1 in IPF fibroblasts (Fig. S9A). TGF-β1 impaired mitophagy in HFs, as evidenced by the decreased LC3B-II/I, PINK1 and Parkin expression. Notably, danthron enhanced mitophagy, whereas WWL229 reversed this effect (Fig. 6E, F). The increase in autophagic flux by danthron and the decrease by WWL229 were confirmed by the greater accumulation of LC3B-II/I upon bafilomycin A1 (BafA1) treatment under TGF-β1 (Fig. S9B). Using transmission electron microscopy (TEM), a few autophagosomes were observed in TGF-β1-induced HFs, while danthron increased their number and WWL229 reversed this effect (Fig. 6G). Furthermore, we transfected HFs with GFP-LC3 to observe LC3-mitochondria colocalization and analyze mitophagy formation. TGF-β1 inhibited GFP-LC3 puncta formation and mitochondrial colocalization, indicating decreased mitophagy. Danthron enhanced these parameters, whereas WWL229 abrogated this effect (Fig. 6H). Additionally, we also transfected HFs with the mRFP-GFP-LC3 plasmid to detect autophagic flux. TGF-β1 inhibited the formation of autophagosomes (yellow puncta) and autolysosomes (red puncta), while danthron promoted their formation, and WWL229 reversed this effect (Fig. 6I). Danthron enhanced mitochondrial function and promoted mitophagy through upregulating CES3. A The ratio of JC-1 fluorescence intensity in HFs (n = 3). B Relative content of intracellular ATP in HFs (n = 3). C Relative content of lactate in supernatants of HFs (n = 4). D Representative western blot images and quantitative analysis of FN and α-SMA in HFs with lactate stimulation (n = 4). E Representative western blot images and quantitative analysis of Parkin and LC3B in HFs (n = 3). F RT-PCR analysis of PRKN, PINK1, and MAP1LC3B in HFs (n = 4). G Representative autophagic ultrastructure of the HFs under TEM. H Representative confocal images of HFs infected with Ad-GFP-LC3B and stained with Mito-Tracker Deep Red in each group. I Representative confocal images for the formation of autophagosomes (yellow puncta) and autolysosomes (red puncta) in HFs. Scale bar = 1.0 μm (G), 10 μm (H and I). Arrows indicated autophagosomes, and white boxes were used to magnify the typical changes. Data were presented as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001 To provide genetic evidence supporting our results, we generated CES3-overexpressing fibroblasts. After optimizing transfection conditions (1 µg/mL plasmid, Fig. S9C), we found that CES3 overexpression further suppressed the expression of Fibronectin and α-SMA compared to TGF-β1 + Danthron group (Fig. S9D). Furthermore, CES3 acted synergistically with danthron to enhance mitochondrial function, as evidenced by increased ATP levels and LC3B-II/I ratio along with decreased lactate production (Fig. S9E-G). The increase in autophagic flux induced by CES3 overexpression was confirmed by the greater accumulation of LC3B-II/I upon BafA1 treatment (Fig. S9H). Meanwhile, CES3 overexpression increased GFP-LC3B puncta formation and mitochondrial colocalization (Fig. S9I), as well as the accumulation of autophagosomes (yellow puncta) and autolysosomes (red puncta) (Fig. S9J). In addition, we performed immunostaining of mouse lung sections to observe the colocalization of fibroblasts with LC3B and PINK1. Results showed that danthron enhanced mitophagy in fibroblasts, which was reversed by WWL229 (Fig. 7A, B). Importantly, danthron alone did not affect mitophagy gene expression in healthy mice (Fig. S10). Taken together, danthron exerted its anti-fibrotic effects by improving mitochondrial function and enhancing mitophagy through the upregulation of CES3. Danthron enhanced mitophagy in a BLM-induced mouse model, which was reversed by WWL229. A, B Representative immunostaining of PINK1 and LC3B in mouse lung fibroblasts. Scale bar = 50 μm CES3 was downregulated in IPF lung tissues Based on the previous data, we proposed that CES3 exerted a protective role in PF. To explore whether this gene could be a new target for clinical treatment, we examined the levels of CES3 in IPF patients using the online public database. Analysis of the GSE47460 dataset revealed decreased CES3 expression in IPF patients, which exhibited a negative correlation with collagen synthesis genes (COL1A2, COL3A1, COL5A1, COL5A2, COL4A1, and COL24A1) and TGFB1 (Fig. 8A, B). Similarly, within the GSE53845 dataset, a significant negative correlation was identified between CES3 and pro-fibrotic genes (COL4A3, COL4A4, COL24A1, and FN1) (Fig. 8C). In addition, we verified CES3 expression by immunostaining. The results suggested that CES3 was reduced in IPF fibroblasts, which was consistent with our previous data (Fig. 8D). Meanwhile, CES3 was observed to co-localize with CD68, pro-SPC and Vimentin, indicating widespread expression of CES3 in normal lung cells (Fig. S11A-C). Collectively, our findings implied that CES3 might represent a potential target for PF. Decreased CES3 expression in IPF lung tissues. A Differential expression of CES3 in IPF patients as compared to control subjects in GSE47460. B Correlation of CES3 with collagen synthesis genes and TGFB1 in GSE47460. C Correlation of CES3 with pro-fibrotic genes in GSE53845. D Representative immunostaining of CES3 in human lung fibroblasts. Scale bar = 50 μm. Data were presented as mean ± SEM, ***p < 0.001 Discussion IPF is a severe and progressive disease characterized by complex pathogenesis and restricted treatment options, resulting in a substantial healthcare burden worldwide. The primary pharmaceutical interventions, pirfenidone and nintedanib, provide only partial relief from disease progression but often cause gastrointestinal disturbances and other adverse reactions [3, 17, 18]. Therefore, it is imperative to investigate alternative therapeutic agents that offer enhanced efficacy and safety profiles. Danthron, a natural anthraquinone derivative extracted from the traditional Chinese medicine rhubarb, exhibits various pharmacological effects. Previous studies have demonstrated that danthron confers protective effects against metabolic disorders through modulation of lipid metabolism and maintenance of mitochondrial homeostasis [10, 19]. Concurrently, this anthraquinone derivative exhibits promising antineoplastic properties by attenuating intracellular ROS production and suppressing angiogenesis [9]. Nevertheless, investigators have raised legitimate concerns regarding its potential carcinogenicity. These paradoxical findings suggest that danthron may elicit context-dependent effects across diverse pathophysiological conditions. Our study now demonstrates that danthron exerts a robust anti-fibrotic effect in both the BLM-induced mouse model and pro-fibrotic solution-stimulated hPCLS model. Despite the potential adverse effects of dantron, our study provides evidence that dantron could serve as a valuable experimental tool for the identification of novel anti-fibrotic targets. The predominant pathological characteristic of IPF involves the excessive aggregation of myofibroblasts, which are chiefly responsible for the excessive deposition of ECM and the consequent tissue remodeling [20–22]. TGF-β signaling promotes myofibroblast formation through metabolic reprogramming, which is reflected in the modulation of mitochondrial biogenesis and glycolysis [23]. Targeting these pathological mechanisms shows promise for developing novel therapeutics. As demonstrated in our data, danthron not only inhibits the FMT through upregulating CES3 expression, but also promotes the dedifferentiation of established myofibroblasts. CES3, a carboxylesterase isoform that hydrolyzes both endogenous lipids and xenobiotics [24], serves as a pleiotropic checkpoint governing metabolic reprogramming, immune homeostasis, and tumor microenvironmental crosstalk [25, 26]. We demonstrate that danthron-induced CES3 amplifies mitophagy, improves mitochondrial function, and thereby inhibits fibroblast activation, conferring appreciable anti-fibrotic effects. Mitochondrial dysfunction and the resulting metabolic alterations are critical for the pathophysiology of fibrosis, activating fibroblasts to a pro-fibrotic phenotype, and inducing persistent PF [27–29]. Within healthy cells, mitophagy acts as a quality control mechanism, preserving mitochondrial homeostasis by removing damaged mitochondria [30–32]. Consistent with previous reports, we observed that TGF-β1 stimulation disrupted mitochondrial homeostasis and impaired mitophagy in fibroblasts, while danthron significantly ameliorated mitochondrial dysfunction in fibroblasts by restoring of MMP, increasing ATP production, and decreasing lactate synthesis. We further found danthron upregulated the expression of LC3B, Parkin and PINK1, and the formation of autophagosomes. Additionally, the CES3-specific inhibitor WWL229 abolished danthron's protective effects both in vivo and in vitro, while CES3 overexpression amplified its mitochondrial benefits. Although our human specimens and independent cohorts from the public GEO dataset reveal an inverse correlation between CES3 and profibrotic markers, together with reduced CES3 abundance in patients with PF, its ubiquitous expression and pleiotropic physiological roles underscore the need for further mechanistic and translational studies to fully delineate its potential clinical relevance in pulmonary fibrosis. Beyond inhibiting fibroblast activation, eliminating pathological myofibroblasts is critical for resolving fibrosis. Myofibroblast dedifferentiation involves the reversion of activated myofibroblasts to a less differentiated state, restoring their susceptibility to apoptosis and decreasing ECM production [33, 34]. Our findings demonstrated that danthron promoted myofibroblast dedifferentiation by driving cells to an apoptosis-sensitive phenotype. Mechanistically, this restoration was associated with the downregulation of the pro-survival genes and upregulation of the pro-apoptotic genes. Despite these promising findings, our study has several limitations. Although the BLM-induced pulmonary fibrosis model is the most widely utilized preclinical model for IPF, its self-limiting fibrotic response prevents it from recapitulating the chronic, progressive features of clinical IPF, which may impede the direct extrapolation of our study's findings to the clinical setting of human IPF. Furthermore, despite the definitive conclusions drawn from our mouse model and validation using publicly available human datasets, the present study only included lung samples from three IPF patients, which represents a key limitation that warrants further validation in subsequent research. In summary, our study indicated that danthron showed potential as an effective experimental tool for identifying relevant targets in PF. Mechanically, danthron inhibited fibroblast activation primarily through its ability to enhance mitochondrial function and mitophagy by upregulating CES3 expression, thereby highlighting CES3 as a potential therapeutic target for PF treatment. Additionally, danthron promoted myofibroblast dedifferentiation by driving cells toward an apoptosis-sensitive phenotype. Supplementary Information Supplementary Material 1. Acknowledgements We would like to express our gratitude to the individuals who have donated their lung tissues in this study. Abbreviations Idiopathic pulmonary fibrosis Pulmonary fibrosis Bleomycin Extracellular matrix Precision-cut lung slices Human fibroblast Carboxylesterase 3 Transforming growth factor-β1 Connective tissue growth factor Fibroblast-to-myofibroblast transition Alanine aminotransferase Aspartate aminotransferase Creatinine Reactive oxygen stress Differentially expressed genes Mitochondrial membrane potential Authors’ contributions BL conducted Investigation, Methodology, and original draft Writing. RX and HZ were primarily responsible for data curation. ZT ensured project administration. SW conducted formal analysis. SX, DY and JZ participated in resources while JX took charge of funding acquisition and supervision. All authors approved the manuscript. Funding This study was supported by the National Natural Science Foundation of China (No. 82170049, 81973986), the Leading talents of public health in Hubei Province (2022SCZ047), the Clinical Collaboration Project of Traditional Chinese and Western Medicine in the Major Difficult Diseases in Hubei Province (Respiratory system Diseases), the Project of Key R&D Program in Hubei Province (2023BCB127) and Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0506300). Data availability All data generated or analyzed during this study are included in this published article and its Additional files. Declarations Ethics approval and consent to participate For human samples: all studies involving human lung tissues were approved by the Human Assurance Committee of Tongji Hospital (Reference No. TJ-IRB202408057) and signed informed consent for research use of samples were obtained from all subjects. For mouse study: the Animal Care and Use Committee of Tongji Hospital (TJH-202307031) granted approval for all experimental protocols. Animal care and experimental procedures were performed following the Guidelines for Ethical Review of Laboratory Animal Welfare (GB/T 35892–2018). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Sicheng Xu, Email: xu_sicheng@126.com. Danlei Yang, Email: danleiyang@aliyun.com. Jianping Zhao, Email: Zhaojp88@126.com. Jungang Xie, Email: xiejjgg@hotmail.com. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement All data generated or analyzed during this study are included in this published article and its Additional files.